Siegfried Holdings (SGFEF) has reported first-half results showing steady revenue growth and improving profitability metrics across its core business operations.
The Swiss contract development and manufacturing organisation generated revenue of CHF 633 million for the first half, representing a 2.2% increase compared to the same period a year earlier.
Non-GAAP earnings per share came in at CHF 1.56 for the first-half period, reflecting the company’s ability to maintain earnings momentum in a competitive market environment.
Core EBITDA rose to CHF 142 million during the period, up from CHF 133.9 million recorded in the prior-year first half, marking a meaningful improvement in underlying profitability.
The core EBITDA margin expanded by 80 basis points, signalling that Siegfried is achieving better operational efficiency relative to its growing revenue base.
Margin expansion of this scale suggests the company is successfully managing input costs while scaling its manufacturing and development services for pharmaceutical clients globally.
Siegfried operates across multiple international sites, providing drug substance and drug product manufacturing services to some of the world’s largest pharmaceutical and biotech companies.
The contract drug manufacturing sector has seen sustained demand as large pharmaceutical firms increasingly outsource production to specialised partners with established regulatory track records.
Siegfried’s ability to grow revenue while simultaneously improving margins is a positive indicator heading into the second half, where management has reaffirmed its full-year financial outlook.
The company’s decision to reaffirm its full-year guidance signals management confidence in the business pipeline and the strength of existing client relationships carrying into the remainder of the year.
Investors in SGFEF will be watching closely to see whether the margin improvements demonstrated in the first half can be sustained or extended further as the company approaches its year-end targets.
The results reinforce Siegfried’s positioning as a significant player in the contract pharmaceutical manufacturing space, with consistent top-line growth and expanding profitability supporting its long-term growth strategy.
